Exhibit 16.1




                           Dauphin Technology Inc. and
             Preferred Shareholders Settle and Dismiss Legal Actions


FOR IMMEDIATE RELEASE

SCHAUMBURG,  Ill., May 17, 2006  /PRNewswire-FirstCall/  -- Dauphin  Technology,
Inc. ("Dauphin"), a publicly traded company based in Schaumburg,  Illinois whose
common stock trades on the Pink Sheets  Electronic  Quotation  Service under the
symbol  "DNTK.PK"  today  announced  that it and the  holders  of its  Series  A
Preferred  Stock have entered into a settlement  agreement  resolving  all legal
actions  between them.  All pending legal  proceedings  have been dismissed with
prejudice.  The settlement is intended to accelerate  Dauphin's efforts to merge
with GeoVax,  Inc., a development  stage  biotechnology  company  established to
develop,  license and  commercialize  the manufacture and sale of human vaccines
for diseases  caused by the Human  Immunodeficiency  Virus and other  infectious
agents.  On January 24, 2006,  Dauphin and GeoVax announced their execution of a
definitive Agreement and Plan of Merger (the "Merger Agreement").

The  settlement  confirms the parties'  mutual desire to proceed with the GeoVax
merger,  based upon a conversion and exchange of the 10,000,000 shares of Series
A Preferred Stock at the closing of the merger for 20,000,000  common shares, as
anticipated and incorporated in the previously announced Merger Agreement.

"I am pleased  at having  this  matter  behind us and being able to focus on our
merger  plans.  Additionally,  I am satisfied  with the terms of the  settlement
which allow us to move forward on a  cooperative  and  supportive  basis towards
fulfillment  and closure of the merger.  This renewed  cooperative  interest and
positive climate between us is further reflected by the preferred  shareholders'
expression of a desire to assist the Company's  working capital efforts," stated
Andrew J. Kandalepas, CEO and Chairman of Dauphin Technology, Inc.

Don Hildebrand,  GeoVax Inc.  President/CEO  commented,  "GeoVax is very pleased
that  Dauphin and its  preferred  stockholders  have  resolved  issues that were
slowing  down our planned  merger.  We are looking  forward to  concluding  this
mutually  beneficial  merger at the earliest  possible date in  accordance  with
previously  agreed terms. Our human trials  evaluating  GeoVax AIDS vaccines are
continuing at several sites in the USA."

For More Information, Contact:
Dauphin Technology, Inc.
(847) 303-6566

No Stock Exchange has reviewed nor accepted  responsibility  for the adequacy or
accuracy  of the  contents  of this news  release,  which has been  prepared  by
management.  Statements  contained in this news release that are not  historical
facts are  forward-looking  statements as that term is defined within the ``safe
harbor'' provision as contained in the private securities  litigation reform act
of 1995.Such  forward-looking  statements are subject to risks and uncertainties
that could cause actual results to differ materially from estimated results.